Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular Carcinoma

An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.

Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.

A key opinion leader in liver cancer reviews the study design of the REFLECT trial of lenvatinib in patients with HCC and shares key insights into its safety and efficacy data.

An expert hematologist-oncologist considers the potential role of combination therapy with lenvatinib for patients with hepatocellular carcinoma.

A thought leader in the management of hepatocellular carcinoma provides an overview of several clinical trials of combination therapy with lenvatinib including studies of real-world evidence and potential biomarkers.

Richard S. Finn, MD concludes the discussion by commenting on areas of unmet need in the care of HCC and emphasizes the potential impact of trials studying treatment combination and sequencing.